ASPHO Webinars Connect Learners to the Latest in Pediatric Hematology/Oncology Clinical Treatment, Best Practices, and Professional Development

Click each webinar title above for program descriptions and to register.

This two-part webinar series, "Harnessing Immunity Without Harm," addresses the growing need for education on immunotherapy-related toxicities in pediatric hematology/oncology/bone marrow transplant, covering (Part 1) immunosuppressant monitoring and (Part 2) immune-related adverse events of novel immunotherapies such as checkpoint inhibitors and CAR-T cells.

As immunomodulatory therapies expand across hematologic and oncologic diagnoses, providers must be equipped to recognize, prevent, and manage potentially life-threatening toxicities associated with these treatments. A foundational understanding of immunology and the immune mechanisms targeted by these therapies is essential yet often underemphasized in clinical training. This interdisciplinary series is designed to bridge that knowledge gap for providers across multiple disciplines and training stages who care for children receiving these increasingly common therapies.

Moderators:
Part 1, Monday, October 26 at 3 PM CT
Moderator: Taylor Kim, MD, CHLA
Clinical Immunology SIG Vice-Chair

Part 2, Monday, November 2 at 3 PM CT
Moderator: Shipra Kaicker, MD
Weill Cornell Medicine, NewYork-Presbyterian Hospital

Speakers:
Michele P. Lambert, M.D., MSTR
Children's Hospital of Philadelphia

Holly Miller, DO
Phoenix Children's

Learning Objectives:

1. Understand the side effects of immunosuppressive medications and recognize the appropriate monitoring required
2. Recognize immune-related adverse events of immunotherapies including management strategies

Click each webinar title above for program descriptions and to register.

Are you feeling overwhelmed, drained, or disconnected? You're not alone—burnout is a widespread challenge among pediatric hematology/oncology providers.

Join us for an engaging and practical webinar that will explore factors contributing to stress and identify ways to bolster professional fulfillment. Learn how communication skills, grounded in models like Stanford's WELLMD, can serve as powerful tools to boost resilience, foster empathy, and create a more fulfilling work environment. Hear real-world stories, share your experiences, and explore innovative strategies—such as mindfulness, boundary-setting, and relational communication—that you can apply immediately.

This session isn't just about understanding burnout; it's about empowering you with actionable techniques to protect your wellbeing, improve your interactions, and thrive in your demanding role.

Let's work together to reignite a healthier, more compassionate, and sustainable hematology/oncology community.

Moderator:
Kelsie-Marie Offenwanger, Psy. D
Sanford Health - Marshfield Children's Hospital

Speakers:
Kara Kelly, CPNP-AC
UT Southwestern Medical Center/ Children's Health

Kathleen Sakamoto, M.D., Ph.D.
Stanford University/Lucile Packard Children's Hospital

Johnson, APRN-PNP
Mayo Clinic

Learning Objectives:

1. Explore factors contributing to burnout and professional fulfillment
2. Discuss how communication skills intersect with the WELLMD domains of professional fulfillment
3. Share best practices and experiences related to well-being including communication strategies, mindfulness, empathy, and boundary-setting strategies

Speaker:
Tammuella Chrisentery- Singleton, MD

Program Synopsis:
This program will focus on an ultra-rare bleeding disorder, Hereditary Factor X Deficiency (HFXD). Attendees will learn more about this severe bleeding disorder, including symptoms, testing, and unique severity scale. During this session, Dr. Singleton will also discuss the burden of disease, current treatment landscape, considerations for patient management, and the role of single-factor replacement, COAGADEX, in the treatment of HFXD.

Indications and Usage for COAGADEX
COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children with hereditary factor X deficiency for:

• Routine prophylaxis to reduce the frequency of bleeding episodes
• On-demand treatment and control of bleeding episodes
• Perioperative management of bleeding in patients with mild, moderate and severe hereditary factor X deficiency

Contraindication for COAGADEX
COAGADEX is contraindicated in patients who have had life-threatening hypersensitivity reactions to COAGADEX.

Important Safety Information for COAGADEX
Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately, contact their physician, and administer appropriate treatment.

The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.

COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.

In clinical studies, the most common adverse reactions (frequency ≥5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.

Please see complete Prescribing Information for COAGADEX.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also call Kedrion at 1-866-398-0825 or email This email address is being protected from spambots. You need JavaScript enabled to view it. .